This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de la Taille, A. Articles by Chopin, D. Search for Related Content PubMed PubMed Citation Articles by de la Taille, A. Articles by Chopin, D.

ß-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells¹

Department of Urology, Assistance Publique des Hôpitaux de Paris-CHU Mondor, 94000 Créteil, France [A. d. l. T., F. V., S. G-D. d. M., D. C.]; Department of Pathology and Urology, University of Michigan, Ann Arbor, Michigan [M. A. R.]; and Department of Pathology and Urology, Columbia University, New York, New York [M-W. C., M. B., R. B.]

Purpose: ß-Catenin is a critical end component of the wnt signaling pathway that regulates cell growth, apoptosis, and migratory behavior in response to intercellular adhesion molecules. The aim of this study was to evaluate abnormalities of ß-catenin protein expression, subcellular localization, and activity in an in vitro model of acquired apoptosis-resistance in cultured PC cells and in primary human prostate cancers (PrCa).

Experimental Design: Apoptosis-resistant human prostate cancer cell line variants were derived from parental LNCaP cells by repeated brief exposure to apoptotic stimuli. The derivative and parental cells were analyzed for ß-catenin expression and intracellular localization using cell fractionation and Western blotting procedures. Endogenous transcriptional activity from the TCF/LEF-1 response element was also studied in these variants after transfection with a ß-catenin sensitive reporter plasmid. Finally, ß-catenin protein expression and intracellular localization were evaluated on 212 patients [122 localized PrCa and 90 hormone-refractory (HRPC) PrCa specimens by immunohistochemistry].

Results: Western blot analysis showed that the intracellular partitioning of ß-catenin was shifted from the membrane fraction in parental cells to the cytoplasmic/nuclear fractions of the apoptosis-resistant cell lines. Coordinately, transcriptional activity from a TCF/LEF-promoted reporter plasmid was increased significantly in the apoptosis-resistant lines. In the primary prostate tumors analyzed, cytoplasmic and/or nuclear ß-catenin expression was correlated statistically with the HRPC status and Gleason score. In the group of localized PrCa, abnormal ß-catenin expression tended to be associated with a higher Gleason score and with pT3 disease. No mutation was found in patients with HRPC and abnormal ß-catenin expression.

Conclusion: These data suggest that anomalies of ß-catenin expression occur in PrCa and that these anomalies are associated with disease progression, especially to the therapeutic-resistant state.

This article has been cited by other articles:

				M. Saleem, I. Murtaza, R. S. Tarapore, Y. Suh, V. M. Adhami, J. J. Johnson, I. A. Siddiqui, N. Khan, M. Asim, B. B. Hafeez, et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting {beta}-catenin signaling Carcinogenesis, May 1, 2009; 30(5): 808 - 817. [Abstract] [Full Text] [PDF]

				P. Mendiratta, E. Mostaghel, J. Guinney, A. K. Tewari, A. Porrello, W. T. Barry, P. S. Nelson, and P. G. Febbo Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer J. Clin. Oncol., April 20, 2009; 27(12): 2022 - 2029. [Abstract] [Full Text] [PDF]

				S. J. Assinder, Q. Dong, H. Mangs, and D. R. Richardson Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-{beta} Pathways in Prostate Cancer Mol. Pharmacol., March 1, 2009; 75(3): 429 - 436. [Abstract] [Full Text] [PDF]

				G. Wang, J. Wang, and M. D. Sadar Crosstalk between the Androgen Receptor and {beta}-Catenin in Castrate-Resistant Prostate Cancer Cancer Res., December 1, 2008; 68(23): 9918 - 9927. [Abstract] [Full Text] [PDF]

				G.-Y. Song, J.-H. Lee, M. Cho, B.-S. Park, D.-E. Kim, and S. Oh Decursin Suppresses Human Androgen-Independent PC3 Prostate Cancer Cell Proliferation by Promoting the Degradation of beta-Catenin Mol. Pharmacol., December 1, 2007; 72(6): 1599 - 1606. [Abstract] [Full Text] [PDF]

				S. Shukla, G. T. MacLennan, C. A. Flask, P. Fu, A. Mishra, M. I. Resnick, and S. Gupta Blockade of {beta}-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice Cancer Res., July 15, 2007; 67(14): 6925 - 6935. [Abstract] [Full Text] [PDF]

				S.-Y. Chen, G. Wulf, X. Z. Zhou, M. A. Rubin, K. P. Lu, and S. P. Balk Activation of {beta}-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-{beta}-Catenin Interaction Mol. Cell. Biol., February 1, 2006; 26(3): 929 - 939. [Abstract] [Full Text] [PDF]

				P. Sun, H. Xiong, T. H. Kim, B. Ren, and Z. Zhang Positive Inter-Regulation between beta-Catenin/T Cell Factor-4 Signaling and Endothelin-1 Signaling Potentiates Proliferation and Survival of Prostate Cancer Cells Mol. Pharmacol., February 1, 2006; 69(2): 520 - 531. [Abstract] [Full Text] [PDF]

				X. Zi, Y. Guo, A. R. Simoneau, C. Hope, J. Xie, R. F. Holcombe, and B. H. Hoang Expression of Frzb/Secreted Frizzled-Related Protein 3, a Secreted Wnt Antagonist, in Human Androgen-Independent Prostate Cancer PC-3 Cells Suppresses Tumor Growth and Cellular Invasiveness Cancer Res., November 1, 2005; 65(21): 9762 - 9770. [Abstract] [Full Text] [PDF]

				X. Yang, M.-W. Chen, S. Terry, F. Vacherot, D. K. Chopin, D. L. Bemis, J. Kitajewski, M. C. Benson, Y. Guo, and R. Buttyan A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells Cancer Res., June 15, 2005; 65(12): 5263 - 5271. [Abstract] [Full Text] [PDF]

				D. Lodygin, A. Epanchintsev, A. Menssen, J. Diebold, and H. Hermeking Functional Epigenomics Identifies Genes Frequently Silenced in Prostate Cancer Cancer Res., May 15, 2005; 65(10): 4218 - 4227. [Abstract] [Full Text] [PDF]

				D.A. LAWSON, L. XIN, R. LUKACS, Q. XU, D. CHENG, and O.N. WITTE Prostate Stem Cells and Prostate Cancer Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 187 - 196. [Abstract] [PDF]

				H. Zhu, M. Mazor, Y. Kawano, M. M. Walker, H. Y. Leung, K. Armstrong, J. Waxman, and R. M. Kypta Analysis of Wnt Gene Expression in Prostate Cancer: Mutual Inhibition by WNT11 and the Androgen Receptor Cancer Res., November 1, 2004; 64(21): 7918 - 7926. [Abstract] [Full Text] [PDF]

				D. Masiello, S.-Y. Chen, Y. Xu, M. C. Verhoeven, E. Choi, A. N. Hollenberg, and S. P. Balk Recruitment of {beta}-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells Mol. Endocrinol., October 1, 2004; 18(10): 2388 - 2401. [Abstract] [Full Text] [PDF]

				W. D Stein, T. Litman, T. Fojo, and S. E Bates A Serial Analysis of Gene Expression (SAGE) Database Analysis of Chemosensitivity: Comparing Solid Tumors with Cell Lines and Comparing Solid Tumors from Different Tissue Origins Cancer Res., April 15, 2004; 64(8): 2805 - 2816. [Abstract] [Full Text] [PDF]

				D. R. Chesire, T. A. Dunn, C. M. Ewing, J. Luo, and W. B. Isaacs Identification of Aryl Hydrocarbon Receptor as a Putative Wnt/{beta}-Catenin Pathway Target Gene in Prostate Cancer Cells Cancer Res., April 1, 2004; 64(7): 2523 - 2533. [Abstract] [Full Text] [PDF]